Annual report 2024
A unique network with strong partners.
Key figures
Financial key figures
Net sales
in million CHF
EBIT adjusted
in million CHF
Number of employees
as of 31 December 2024
Management report
Sales of the Galenica Group performed very pleasingly in 2024, with growth of 4.7% to CHF 3,921.1 million. The main growth driver was the “Logistics & IT” segment, which achieved sales growth of 5.3% thanks to market share gains in the wholesale business with doctors and pharmacies. The “Products & Care” segment also recorded a favourable performance with sales growth of 3.9%, supported by strong growth in prescription-only medications and the acquisition of new pharmacies.
Report on non-financial matters pursuant to Art. 964a et seq. of the Swiss Code of Obligations
In this report, we provide information on our performance, due diligence, objectives and risks in the areas of the environment, society, employees, human rights and anti-corruption.
«The online presence of Galenica pharmacies will be further developed and strengthened as an important part of the Omni-Channel strategy.»
Stephan Mignot, Chief Pharmacies Marketing